Analytical exoglycosidases are transitioning from being largely academic tools to being suitable for glycan analytics in biopharmaceutical manufacturing.
Xiaofeng Shi
Advertisement
Xiaofeng Shi is development group leader at New England Biolabs.
Articles by Xiaofeng Shi
Advertisement
Latest Updated Articles
Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic DrugsPublished: October 1st 2018 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
5
